In:
Current Computer-Aided Drug Design, Bentham Science Publishers Ltd., Vol. 20, No. 3 ( 2024-06), p. 291-302
Abstract:
Non-Hodgkin’s Lymphoma (NHL) is a series of lymphoid malignancies
in some aggressive subtypes with unsatisfactory treatment effects. Allii Macrostemonis Bulbus (Xie Bai) is a traditional Chinese medicine with anti-cancer activities, which may potentially suppress
aggressive NHL. Objective: This study tries to discover active components and targets of Xie Bai in treating NHL
by network pharmacology-based approaches. Methods: Compounds and related targets of Xie Bai were collected from the Traditional Chinese
Medicine Database and Analysis Platform. Target genes associated with NHL were searched by GeneCards and DisGeNET, then the overlapped targets were further analyzed by STRING tool,
GO, and KEGG pathway enrichment analysis. Molecular docking was employed to verify the interaction between compounds and targets. Results: 11 bioactive compounds were successfully identified, with 30 targets that were screened
out for the treatment of NHL. Functional enrichment analysis suggested that Xie Bai exerted its potential effects against NHL via pathways in cancer, such as PI3K/ AKT, p53, and MAPK signaling
pathways. Molecular docking results showed that 3 active compounds (quercetin, betasitosterol, and naringenin) had good affinity with selected 6 targets (TP53, AKT1, CASP3,
CCND1, HPK1, and NLRP3). Conclusion: Identifying six potential genes could accurately be docked with Xie Bai and had
close interactions with NHL, which may provide insight into further research and new treatment strategy.
Type of Medium:
Online Resource
ISSN:
1573-4099
DOI:
10.2174/1573409919666230712144041
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2024
SSG:
15,3
Permalink